Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIKAYCE in Mycobacterium abscessus lung disease
NCT03038178Phase 2Completed
- Sponsor
- Kevin Winthrop
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease, sponsored by Kevin Winthrop. Started Oct 2016; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on NCT03038178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038178.